2021
Clinical PET/CT utilization during the COVID-19 pandemic: initial experience at Yale University
Adin ME, Uezono H, Isufi E, Pang Y, Zucconi W, Saperstein L, Pucar D. Clinical PET/CT utilization during the COVID-19 pandemic: initial experience at Yale University. Nuclear Medicine Communications 2021, 42: 1277-1284. PMID: 34049340, PMCID: PMC8527913, DOI: 10.1097/mnm.0000000000001445.Peer-Reviewed Original ResearchConceptsCT utilizationOncologic factorsPET/CT scanningTertiary academic centerPET-CT scanCOVID-19COVID-19 pandemicElectronic medical recordsPublic health recordsScan positivityYounger patientsOncologic dataCOVID-19 casesEpidemiologic trendsHematologic malignanciesMedical recordsEpidemiologic changesSolid cancersCase volumeAcademic centersInitial experienceCT scanningCancer typesHealth recordsPandemic relative
2020
Predictive Value of PET-CT in Patients with T-Cell Lymphoma Undergoing Autologous and Allogeneic Stem Cell Transplant
Isufi I, Chandhok N, Boddu P, Pucar D, Seropian S, Gowda L, Perreault S, Wilson L, Roberts K, Foss F. Predictive Value of PET-CT in Patients with T-Cell Lymphoma Undergoing Autologous and Allogeneic Stem Cell Transplant. Transplantation And Cellular Therapy 2020, 26: s244. DOI: 10.1016/j.bbmt.2019.12.492.Peer-Reviewed Original ResearchRelapse-free survivalPET-CT scanTime of SCTTime of alloSCTPET-CTT-NHLBM biopsyAllo-SCTCT scanPositive PET/CT scanPredictive valueLong-term relapse-free survivalPositive PET-CT scanAllogeneic stem cell transplantPeripheral blood flow cytometryPET/CT scansIntermediate-high riskBlood flow cytometryAggressive clinical courseStem cell transplantT-cell lymphomaMajority of ptsPositive PET-CTAuto-SCTMedian follow
2019
PS1313 FEASIBILITY AND PRELIMINARY RESULTS OF A PROSPECTIVE EVALUATION OF RESIDUAL DISEASE IN DIFFUSE LARGE B‐CELL LYMPHOMAS USING DEEP SEQUENCING OF CELL FREE DNA AND DNA FROM FORMALIN FIXED BIOPSIES
Carniti C, Biancon G, Banfi S, Vella C, Magni M, Pennisi M, Anna D, Guidetti A, Corradini P. PS1313 FEASIBILITY AND PRELIMINARY RESULTS OF A PROSPECTIVE EVALUATION OF RESIDUAL DISEASE IN DIFFUSE LARGE B‐CELL LYMPHOMAS USING DEEP SEQUENCING OF CELL FREE DNA AND DNA FROM FORMALIN FIXED BIOPSIES. HemaSphere 2019, 3: 599-600. DOI: 10.1097/01.hs9.0000563532.69483.ec.Peer-Reviewed Original ResearchCell-free DNADLBCL patientsIgH gene rearrangementTumor burdenResidual diseaseIgH rearrangementsGene rearrangementsDiffuse large B-cell lymphoma patientsLarge B-cell lymphoma patientsB-cell lymphoma patientsDiffuse large B-cell lymphomaLarge B-cell lymphomaPossible disease progressionPossible residual diseaseR-CHOP therapyBaseline plasma samplesLymph node biopsyDisease monitoringImmunoglobulin heavy chain gene rearrangementMultiple myeloma patientsNon-invasive disease monitoringCell lymphoma patientsNumber of patientsFFPE samplesPET-CT scan
2018
Complete metabolic response to therapy of hepatic epithelioid hemangioendothelioma evaluated with 18F-fluorodeoxyglucose positron emission tomography/contrast-enhanced computed tomography
Giancipoli R, Monti S, Basturk O, Klimstra D, Keohan M, Schillaci O, Corrias G, Sawan P, Mannelli L. Complete metabolic response to therapy of hepatic epithelioid hemangioendothelioma evaluated with 18F-fluorodeoxyglucose positron emission tomography/contrast-enhanced computed tomography. Medicine 2018, 97: e12795. PMID: 30334971, PMCID: PMC6211838, DOI: 10.1097/md.0000000000012795.Peer-Reviewed Original ResearchConceptsF-FDG PET/CTDiagnosis of epithelioid hemangioendotheliomaMetabolic response to therapyHepatic epithelioid hemangioendotheliomaF-FDGVascular endothelial growth factorEpithelioid hemangioendotheliomaResponse to therapyAnti-angiogenic agentsF-FDG PET-CT scanInhibitor of vascular endothelial growth factorRare malignant vascular tumorPET-CT scanFollow-up CTMalignant vascular tumorsVariable clinical presentationRight upper quadrantLymph node lesionsMultiple hepatic massesPosttreatment Follow-upEndothelial growth factorFDG avidityCyclophosphamide treatmentF-fluorodeoxyglucoseClinical presentation
2017
Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer.
Di Meglio A, Lin NU, Freedman RA, Barry WT, Winer EP, Vaz-Luis I. Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. Journal Of The National Comprehensive Cancer Network 2017, 15: 316-324. PMID: 28275032, DOI: 10.6004/jnccn.2017.0031.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerDe novo metastatic breast cancerNovo metastatic breast cancerTM testingPET/PET-CTTumor markersBreast cancerPET-CTDisease sitesDana-Farber Cancer InstituteSerum tumor markersTiming of imagingPET-CT scanFrequency of imagingCourse of treatmentPatterns of utilizationAsymptomatic patientsNeurologic symptomsRetrospective cohortClinicopathologic factorsTreatment initiationRadiographic studiesCancer InstitutePatientsTumor subtypes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply